MedPath

Rivoceranib

Generic Name
Rivoceranib
Drug Type
Small Molecule
Chemical Formula
C24H23N5O
CAS Number
811803-05-1
Unique Ingredient Identifier
5S371K6132
Background

Rivoceranib is under investigation in clinical trial NCT02726854 (Apatinib as Second-line Treatment of Advanced Pancreatic Cancer).

Indication

本品单药适用于既往至少接受过2种系统化疗后进展或复发的晚期胃腺癌或胃-食管结合部腺癌患者。患者接受治疗时应一般状况良好。

Clinical Trials
Related News

Phase III Study of Apatinib Tablets in the Treatment of Advanced or Metastatic Gastric Cancer

Phase 3
Completed
Conditions
Advanced or Metastatic Gastric Cancer
Interventions
Drug: placebo
First Posted Date
2012-01-19
Last Posted Date
2016-10-17
Lead Sponsor
Jiangsu HengRui Medicine Co., Ltd.
Target Recruit Count
267
Registration Number
NCT01512745
Locations
🇨🇳

The 81 Hosiptal of PLA, Nanjing, Jiangsu, China

🇨🇳

Fudan University cancer hospital, Shanghai, Shanghai, China

Dose-Escalation and Safety Trial of YN968D1

Phase 1
Completed
Conditions
Cancer Patients With Solid Tumors
Interventions
First Posted Date
2011-12-22
Last Posted Date
2017-10-02
Lead Sponsor
Elevar Therapeutics
Target Recruit Count
55
Registration Number
NCT01497704
Locations
🇰🇷

ASAN Medical Center, Seoul, Korea, Republic of

🇺🇸

Huntsman Cancer Institute, Salt Lake City, Utah, United States

Apatinib in the Treatment of Advanced Non-squamous Non-small Cell Lung Cancer

Phase 3
Conditions
Non-small Cell Lung Cancer
Interventions
Drug: placebo
First Posted Date
2011-02-02
Last Posted Date
2013-12-09
Lead Sponsor
Sun Yat-sen University
Target Recruit Count
480
Registration Number
NCT01287962
Locations
🇨🇳

Cancer Center of Sun Yat-Sen University (CCSU), Guangzhou, Guangdong, China

A Study of Apatinib in Patients With Advanced Non-squamous and Non-small Cell Lung Cancer

Phase 2
Completed
Conditions
Non-Small-Cell Lung Cancer
Interventions
Drug: placebo
First Posted Date
2011-01-05
Last Posted Date
2012-02-10
Lead Sponsor
Jiangsu HengRui Medicine Co., Ltd.
Target Recruit Count
136
Registration Number
NCT01270386
Locations
🇨🇳

Department of Medical Oncology, Cancer Center, Sun Yet-sen University, Guangzhou, Guangdong, China

A Study of Apatinib in Patients With Advanced Hepatocellular Carcinoma

Phase 2
Completed
Conditions
Advanced Hepatocellular Carcinoma
Interventions
First Posted Date
2010-09-01
Last Posted Date
2023-03-03
Lead Sponsor
Jiangsu HengRui Medicine Co., Ltd.
Target Recruit Count
121
Registration Number
NCT01192971
Locations
🇨🇳

Nanjing Millitary Eighty-one Hosiptal, Nanjing, Jiangsu, China

Study of Apatinib in Metastatic Triple-Negative Breast Cancer Patients

Phase 2
Completed
Conditions
Metastatic Breast Cancer
Interventions
First Posted Date
2010-08-06
Last Posted Date
2015-09-09
Lead Sponsor
Fudan University
Target Recruit Count
60
Registration Number
NCT01176669
Locations
🇨🇳

Fudan University Cancer Hospital, Shanghai, Shanghai, China

Apatinib Versus Placebo as a Third Line Treatment in Patients With Advanced or Metastatic Gastric Cancer

Phase 2
Completed
Conditions
Gastric Carcinoma
Interventions
First Posted Date
2009-09-02
Last Posted Date
2011-07-12
Lead Sponsor
Fudan University
Target Recruit Count
141
Registration Number
NCT00970138
Locations
🇨🇳

Fudan University Cancer Hospital, ShangHai, Shanghai, China

Study of Apatinib as an Inhibitor of Tumor Angiogenesis

Phase 1
Conditions
Tumor
Interventions
First Posted Date
2008-03-12
Last Posted Date
2008-07-22
Lead Sponsor
Fudan University
Target Recruit Count
18
Registration Number
NCT00633490
Locations
🇨🇳

Fudan University Cancer Hospital, Shanghai, Shanghai, China

© Copyright 2025. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy